

Active substances set

Search phrase: crizotinib

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Tracheal, bronchus, and lung cancer

Crizotinib	Crizotinib as monotherapy is indicated for: - The first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), - The treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), - The treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).	FULL REIMBURSEMENT ESMO